Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
Table 1
Baseline characteristics of the study patients.
= 36
Age (years)
61.5 (29–72)
Sex (male/female)
19/17
Height (cm)
159.3 (143.1–177.0)
Weight (kg)
62.1 (39.6–81.5)
BMI
24.2 (17.1–35.0)
Genotype (1a/1b)
1/35
Baseline HCV-RNA (LogIU/mL; TaqMan)
6.7 (4.8–7.5)
Response to prior PEG-IFN and ribavirin (NR/Relapse/Naive)
4/18/14
Fatty liver
6
Cirrhosis
18
Diabetes mellitus
7
IL28B, rs8099917 (TT/GT/GG)
24/11/1
Core 70 (wild/mutant/ND)
18/17/1
Core 91 (wild/mutant/ND)
26/9/1
WBC (/mm3)
4785 (2700–9300)
Hb (g/dL)
14.6 (11.6–18.6)
Platelets (/mm3)
16.5 (6.6–28.0)
ALT (IU/L)
46.0 (14–507)
γ-GT (IU/L)
35.5 (10–306)
Type VI collagen 7S (ng/mL)
4.4 (3.1–10.5)
Hyaluronic acid (ng/mL)
98.0 (12.3–839.0)
AFP (ng/mL)
4.5 (1.3–174.6)
Reduced dose regimen
30
Telaprevir adherence (%)
66.7 (0.6–100)
PEG-IFN adherence (%)
66.8 (5.5–100)
Ribavirin adherence (%)
66.7 (2.4–100)
Values are expressed as median (range). BMI, body mass index; HCV, hepatitis C virus; IL, interleukin; ND, not determined; WBC, white blood cells; Hb, hemoglobin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transferase; AFP, alpha-fetoprotein; PEG-IFN, pegylated interferon.
